
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CHCHD2 CRISPR Activation Plasmid (h) | sc-412127-ACT | 20 µg | $397.00 | |||
CHCHD2 CRISPR Activation Plasmid (h2) | sc-412127-ACT-2 | 20 µg | $397.00 |
CHCHD2 (coiled-coil-helix-coiled-coil-helix domain containing 2) encodes a mitochondrial intermembrane space protein implicated in maintaining oxidative phosphorylation efficiency and mitochondrial ultrastructure. It participates in redox homeostasis, respiratory chain function, and stress-responsive signaling that influences apoptosis and mitochondrial quality control. Altered CHCHD2 expression or function has been associated with neurodegeneration and mitochondrial disorders, and it is frequently studied in the context of Parkinson’s disease–related pathways and cellular vulnerability to oxidative stress. In human cells, CHCHD2 provides a tractable node for dissecting mitochondrial signaling crosstalk with nuclear transcriptional programs.
CHCHD2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CHCHD2 expression without altering the underlying DNA sequence.
CHCHD2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CHCHD2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CHCHD2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CHCHD2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CHCHD2 locus and enabling the study of CHCHD2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CHCHD2 pathway restoration in tumor cells with silenced or reduced CHCHD2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.